



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
Bureau for Medical Services

Jeffrey H. Coben, MD
Interim Cabinet Secretary

Cynthia E. Beane
Commissioner

MEMORANDUM

TO: Bureau for Medical Services Providers

FROM: Cynthia Parsons
Director Behavioral Health and Long-Term Care Services

SUBJECT: Removal of the DEA-DATA-Waiver Requirement for Buprenorphine Medications

DATE: February 17, 2023

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the DATA-Waiver Program. All Drug Enforcement Agency (DEA) registrants should be aware of the following:

- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.

Gainwell Technologies and Rational Drug have been notified of these changes and providers are no longer required to send in a request for review and/or send a copy of their DEA-X number effective immediately. Any physician, advanced practice registered nurse, or physician assistant may prescribe buprenorphine products as defined by the DEA.

If you have any questions, please feel free to contact Cynthia Parsons at 304-352-4254
Cynthia.A.Parsons@wv.gov

